The Radiographic Scars of Glucocorticoid Treatment in Systemic Lupus Erythematosus

JANET W. MAYNARD, MD; ALLAN C. GELBER, MD, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Address correspondence to Dr. A.C. Gelber, Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224; E-mail: agelber@jhmi.edu; J Rheumatol 2009;36:1763–4; doi:10.3899/jrheum.081107

A 22-year-old African American woman presented with worsening left hip pain precluding ambulation. Seven years earlier, systemic lupus erythematosus (SLE) was diagnosed in the setting of fatigue, malar rash, polyarthritis, and photosensitivity, with antinuclear antibody, ds-DNA, Smith, ribonucleoprotein, Ro, and La seropositivity. Subsequent manifestations included aseptic meningitis, cutaneous vasculitis, and diffuse proliferative glomerulonephritis. Therapy included cyclophosphamide, prednisone, mycophenolate mofetil, and hydroxychloroquine. Average prednisone dose over 4 years was 20 mg daily.

Two years before presentation, she first developed bilateral hip pain. Radiographs showed flattening of the right femoral head (arrow, Figure 1A), which was preserved on the left side. Magnetic resonance imaging (MRI) revealed bilateral avascular necrosis (AVN) or osteonecrosis. Right total hip replacement and left core decompression surgery were performed, with substantial symptomatic and functional improvement. Nevertheless, 1 year postoperatively, she developed recurrent left hip pain and new left (greater than right) shoulder pain. A pelvis radiograph showed a right total arthroplasty, left core decompression (arrowheads, Figure 1B), and new sclerosis with deformity of the left femoral head (arrow, Figure 1B). Pelvis and shoulder MRI scans showed characteristic "double-line sign"¹ of the left femoral head (arrow, Figure 1C) and left humeral head (arrow, Figure 1D), respectively. The "double-line sign" is observed

on T2-weighted MR images in AVN and represents hypervascular tissue in the necrotic region surrounding a fibrosed and sclerotic zone.

This instructive case illustrates the clinical and radiographic course of a young woman with SLE, and the disease and treatment-related complications. AVN results from bone ischemia, an unintended consequence of glucocorticoid therapy². Patients with SLE, especially those with higher disease activity, are susceptible to develop osteonecrosis³. The most significant risk factor is treatment with ≥ 20 mg daily prednisone⁴. It is essential to recognize possible steroid-associated toxicity, including the progressive musculoskeletal damage illustrated in this case.

REFERENCES

- Mitchell DG, Rao VM, Dalinka MK, et al. Femoral head avascular necrosis: correlation of MR imaging, radiographic staging, radionuclide imaging, and clinical findings. Radiology 1987;162:709-15.
- Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:761-5.
- Fialho SCMS, Bonfá E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 2007;16:239-44.
- Zonan-Nacach A, Barr SB, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2009. All rights reserved.

Maynard and Gelber: Scars of SLE





в





Figure 1. A. Radiograph shows flattening of the right femoral head (arrow). B. Pelvis radiograph shows a right total arthroplasty, left core decompression (arrowheads), and new sclerosis with deformity of the left femoral head (arrow). Pelvis and shoulder MRI scans show characteristic "double-line sign" of the left femoral head (arrow, D) that represents hypervascular tissue in the necrotic region surrounding a fibrosed and sclerotic zone in AVN.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2009. All rights reserved.